GILDGilead Sciences
What is the market doing?
No clear lean: nothing decisive, though in an uptrend.
In an uptrend, above its rising 50- and 200-day averages. Price is +11% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Lightly shorted, settled Sep 15, 2026, about a week of normal trading to cover. Down 20% since the previous count, down from 1.9% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How GILD is trading
Gilead Sciences is +36% over the past year while the S&P 500 is +18%: 17 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +11%
vs 200-day average · a clear uptrend
- RSI (14)
- 51
RSI (14) · neutral
- Below its 52-week high
- 1.8%
Below its 52-week high
Details›
- Last close2026-10-09
- $151.17
- 1 monthS&P 500 +2.7%
- +4.4%
- 1 yearS&P 500 +18%
- +36%
- 5 yearsS&P 500 +88%
- +155%
- vs 50-day average$144.41
- +4.7%
- 52-week high
- $153.91
- 52-week low
- $108.50
- Annualised volatility
- 27%
| Year | Return |
|---|---|
| 2026 (year to date) | +25% |
| 2025 | +37% |
| 2024 | +19% |
| 2023 | −2.0% |
| 2022 | +24% |
| 2021 | +30% |
| 2020 | −6.7% |
| 2019 | +7.9% |
| 2018 | −9.9% |
| 2017 | +3.0% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 6 of 10 | +5.0% |
| Feb | 10 | 3 of 10 | −1.4% |
| Mar | 10 | 5 of 10 | +0.89% |
| Apr | 10 | 3 of 10 | −1.6% |
| May | 10 | 4 of 10 | −1.2% |
| Jun | 10 | 7 of 10 | +3.1% |
| Jul | 11 | 5 of 11 | +1.3% |
| Aug | 11 | 7 of 11 | +2.3% |
| Sep | 11 | 5 of 11 | +0.01% |
| Oct | 11 | 6 of 11 | +0.60% |
| Nov | 10 | 8 of 10 | +4.0% |
| Dec | 10 | 3 of 10 | −1.3% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, General
The closest names by size in the same industry